Neurofibromatosis
Research Highlights/News
2024 | 2023 | 2022 | 2021 | 2020
» Look for consumer stories click here
2024
Research Highlights:
- New Investigator Award Recipients Bring New Ideas to the Neurofibromatosis Research Program for Fiscal Year 2022
- Sleep Disorders Among Children with Neurofibromatosis Type 1 (NF1)
2023
Research Highlights:
- Improving Hearing in NF2 Patients Who Use the Auditory Brainstem Implant (ABI)
- Development of Therapeutic Strategies for NF1-Associated Optic Pathway Glioma
- NFRP Supports Multi-Institutional Synergistic Idea Award to Investigate Inflammation During NF-Related Optic Tumor Formation
- NFRP Funds First Research OTA to Support Neurofibromatosis Clinical Trials
2022
Research Highlights:
- Neurofibromatosis Research Program (NFRP) Research Resources
- Genetic Risk Factors of Schwannoma Tumors
- Pharmacological Alk Inhibition Impacts Behavior and Cognition in Adult NF1 Mutant Mice
2021
Research Highlights:
- Nf1 Mutation Drives Neuronal-Activity-Dependent Initiation of Optic Glioma
- New Investigator Award Recipients Bring New Ideas to the Neurofibromatosis Research Program for Fiscal Year 2020
- Cabozantinib for Neurofibromatosis Type 1-Related Plexiform Neurofibromas: A Phase 2 Trial
- Everolimus Therapy for NF1-Optic Gliomas in Children: A Clinical Trial
2020
Research Highlights:
- The Pain of Neurofibromatosis
- The NFRP Supports the Future of NF Research with Several New Investigator Awards
- The NFRP Joins Efforts to Promote Open Science in NF Research
- Clinical Trials Address Quality of Life for Persons with Neurofibromatosis (NF1, NF2, and Schwannomatosis) with Resiliency Training Delivered via Live Video
- Study Finds That Bevacizumab Treatment for NF2-Related Vestibular Schwannomas Increases Reported Quality of Life in Adults and Children
Last updated Wednesday, September 17, 2025